CSIMarket


Acasti Pharma Inc   (ACST)
Other Ticker:  
 


 

Acasti Pharma Inc

ACST's Financial Statements and Analysis



Acasti Pharma Inc increased second quarter of 2024 net loss per share of $-0.43 compare to net loss per share of $-0.11 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.54 realized in previous quarter.


second quarter of 2024
Earnings Per Share Revenues
$ -0.43 $  0 Mill
$-0.32     Unch.    



Acasti Pharma Inc 's Revenue fell by 0 % in second quarter of 2024 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Acasti Pharma Inc is

More on ACST's Income Statement



Acasti Pharma Inc 's in thesecond quarter of 2024 recorded net loss of $-3.273 million, an improvement compare to net loss of $-4.929 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-4.023 million realized in previous quarter.

More on ACST's Growth

Acasti Pharma Inc Inventories
ACST's Cash flow In the second quarter of 2024 company's net cash flow was $5 million


Acasti Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Acasti Pharma Inc payed $ -3.21 cash per share, on a free-cash flow basis .

Book value grew by 2.66 % sequentially to $8.84 per share.
Tangible Book value grew to $ 2.31 per share from $ 1.98.

Company issued 0.12 million shares or 1.58 % in Sep 30 2023.


More on ACST's Dividends

 Market Capitalization (Millions) 26
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Acasti Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Acasti Pharma Inc had negative $ -3.21 cash flow per share, on a free-cash flow basis .

Book value grew by 2.66 % sequentially to $8.84 per share.
Tangible Book value grew to $ 2.31 per share from $ 1.98.

Company issued 0.12 million shares or 1.58 % in Sep 30 2023.


More on ACST's Balance Sheets

 Market Capitalization (Millions) 26
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Acasti Pharma Inc Earnings

Acasti Pharma Inc Reveals Operating Loss of $2.092 Million in Sep 30 2023 Report

Acasti Pharma Inc Shows Promising Signs of Recovery with Improved...

Acasti Pharma Inc Reports Significant Improvement in Operating Loss, Reflecting a -$4.73 Million Improvement in the Most Recent Fiscal Period



As the earnings season for the April to June 2023 period progresses, various companies have disclosed their earnings, with entities in the Major Pharmaceutical Preparations industry catching the attention of investors. Acasti Pharma Inc (ACST) is one such company that recently announced its financial results, reporting an operating loss of $-4.454 million for the fiscal span closing on June 30, 2023.
This news has been welcomed by investors, seeing it as a positive development for ACST, particularly when compared to the operating loss of $-4.73 million in the first quarter of 2022. The management's efforts to make the company more cost-effective have shown results, as they have successfully re...

Acasti Pharma Inc Reports Operating Shortfall of $38.072 million in Q4 2023 Amidst Evolving Pharmaceutical Preparations Market

The Major Pharmaceutical Preparations industry advisors are currently analyzing the financial performance of Acasti Pharma Inc for the fourth quarter of 2023. The company has reported an operating shortfall of $-38.072 million for the period from January to March 31, 2023. It is important to note that Acasti Pharma Inc has not reported any revenue yet for this quarter.
To understand the significance of the financial data for the fourth quarter of 2023, it is useful to compare it with the figures from the previous year. In the fourth quarter of 2022, the operating shortfall was $-4.403 million. It is not surprising that the evolving business has recorded a larger shortfall of $-29.087 million in the corre...


Date modified: 2023-11-14T22:27:34+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com